The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Metabotropic Glutamate Antagonists Market Research Report 2025
Synopsis
Metabotropic Glutamate Antagonists act by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly divided into two major subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
Global Metabotropic Glutamate Antagonists market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Metabotropic Glutamate Antagonists market research.
Key manufacturers engaged in the Metabotropic Glutamate Antagonists industry include Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, Purdue Biopharma, Relmada Therapeutics, BioCrea GmbH and Cerecor Inc., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Metabotropic Glutamate Antagonists were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Metabotropic Glutamate Antagonists market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Metabotropic Glutamate Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Artemis Neuroscience
VistaGen Therapeutics
Rottapharm Madaus
Amorsa Therapeutics
Newron Pharmaceuticals
Purdue Biopharma
Relmada Therapeutics
BioCrea GmbH
Cerecor Inc.
NeurOp Inc.
UCB SA
Novartis AG
Luc Therapeutics Inc.
Evotec AG
Segment by Type
Ionic
Non Ionic
Segment by Application
Hospitals And Clinics
Research Institutes
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Metabotropic Glutamate Antagonists report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Metabotropic Glutamate Antagonists act by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly divided into two major subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
Global Metabotropic Glutamate Antagonists market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Metabotropic Glutamate Antagonists market research.
Key manufacturers engaged in the Metabotropic Glutamate Antagonists industry include Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, Purdue Biopharma, Relmada Therapeutics, BioCrea GmbH and Cerecor Inc., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Metabotropic Glutamate Antagonists were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Metabotropic Glutamate Antagonists market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Metabotropic Glutamate Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Artemis Neuroscience
VistaGen Therapeutics
Rottapharm Madaus
Amorsa Therapeutics
Newron Pharmaceuticals
Purdue Biopharma
Relmada Therapeutics
BioCrea GmbH
Cerecor Inc.
NeurOp Inc.
UCB SA
Novartis AG
Luc Therapeutics Inc.
Evotec AG
Segment by Type
Ionic
Non Ionic
Segment by Application
Hospitals And Clinics
Research Institutes
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Metabotropic Glutamate Antagonists report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Metabotropic Glutamate Antagonists Market Overview
1.1 Product Overview and Scope of Metabotropic Glutamate Antagonists
1.2 Metabotropic Glutamate Antagonists Segment by Type
1.2.1 Global Metabotropic Glutamate Antagonists Market Value Comparison by Type (2023-2029)
1.2.2 Ionic
1.2.3 Non Ionic
1.3 Metabotropic Glutamate Antagonists Segment by Application
1.3.1 Global Metabotropic Glutamate Antagonists Market Value by Application: (2023-2029)
1.3.2 Hospitals And Clinics
1.3.3 Research Institutes
1.3.4 Others
1.4 Global Metabotropic Glutamate Antagonists Market Size Estimates and Forecasts
1.4.1 Global Metabotropic Glutamate Antagonists Revenue 2018-2029
1.4.2 Global Metabotropic Glutamate Antagonists Sales 2018-2029
1.4.3 Global Metabotropic Glutamate Antagonists Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Metabotropic Glutamate Antagonists Market Competition by Manufacturers
2.1 Global Metabotropic Glutamate Antagonists Sales Market Share by Manufacturers (2018-2023)
2.2 Global Metabotropic Glutamate Antagonists Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Metabotropic Glutamate Antagonists Average Price by Manufacturers (2018-2023)
2.4 Global Metabotropic Glutamate Antagonists Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Metabotropic Glutamate Antagonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Metabotropic Glutamate Antagonists, Product Type & Application
2.7 Metabotropic Glutamate Antagonists Market Competitive Situation and Trends
2.7.1 Metabotropic Glutamate Antagonists Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Metabotropic Glutamate Antagonists Players Market Share by Revenue
2.7.3 Global Metabotropic Glutamate Antagonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Metabotropic Glutamate Antagonists Retrospective Market Scenario by Region
3.1 Global Metabotropic Glutamate Antagonists Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Metabotropic Glutamate Antagonists Global Metabotropic Glutamate Antagonists Sales by Region: 2018-2029
3.2.1 Global Metabotropic Glutamate Antagonists Sales by Region: 2018-2023
3.2.2 Global Metabotropic Glutamate Antagonists Sales by Region: 2024-2029
3.3 Global Metabotropic Glutamate Antagonists Global Metabotropic Glutamate Antagonists Revenue by Region: 2018-2029
3.3.1 Global Metabotropic Glutamate Antagonists Revenue by Region: 2018-2023
3.3.2 Global Metabotropic Glutamate Antagonists Revenue by Region: 2024-2029
3.4 North America Metabotropic Glutamate Antagonists Market Facts & Figures by Country
3.4.1 North America Metabotropic Glutamate Antagonists Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Metabotropic Glutamate Antagonists Sales by Country (2018-2029)
3.4.3 North America Metabotropic Glutamate Antagonists Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Metabotropic Glutamate Antagonists Market Facts & Figures by Country
3.5.1 Europe Metabotropic Glutamate Antagonists Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Metabotropic Glutamate Antagonists Sales by Country (2018-2029)
3.5.3 Europe Metabotropic Glutamate Antagonists Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Metabotropic Glutamate Antagonists Market Facts & Figures by Country
3.6.1 Asia Pacific Metabotropic Glutamate Antagonists Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Metabotropic Glutamate Antagonists Sales by Country (2018-2029)
3.6.3 Asia Pacific Metabotropic Glutamate Antagonists Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Metabotropic Glutamate Antagonists Market Facts & Figures by Country
3.7.1 Latin America Metabotropic Glutamate Antagonists Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Metabotropic Glutamate Antagonists Sales by Country (2018-2029)
3.7.3 Latin America Metabotropic Glutamate Antagonists Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Metabotropic Glutamate Antagonists Market Facts & Figures by Country
3.8.1 Middle East and Africa Metabotropic Glutamate Antagonists Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Metabotropic Glutamate Antagonists Sales by Country (2018-2029)
3.8.3 Middle East and Africa Metabotropic Glutamate Antagonists Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Metabotropic Glutamate Antagonists Sales by Type (2018-2029)
4.1.1 Global Metabotropic Glutamate Antagonists Sales by Type (2018-2023)
4.1.2 Global Metabotropic Glutamate Antagonists Sales by Type (2024-2029)
4.1.3 Global Metabotropic Glutamate Antagonists Sales Market Share by Type (2018-2029)
4.2 Global Metabotropic Glutamate Antagonists Revenue by Type (2018-2029)
4.2.1 Global Metabotropic Glutamate Antagonists Revenue by Type (2018-2023)
4.2.2 Global Metabotropic Glutamate Antagonists Revenue by Type (2024-2029)
4.2.3 Global Metabotropic Glutamate Antagonists Revenue Market Share by Type (2018-2029)
4.3 Global Metabotropic Glutamate Antagonists Price by Type (2018-2029)
5 Segment by Application
5.1 Global Metabotropic Glutamate Antagonists Sales by Application (2018-2029)
5.1.1 Global Metabotropic Glutamate Antagonists Sales by Application (2018-2023)
5.1.2 Global Metabotropic Glutamate Antagonists Sales by Application (2024-2029)
5.1.3 Global Metabotropic Glutamate Antagonists Sales Market Share by Application (2018-2029)
5.2 Global Metabotropic Glutamate Antagonists Revenue by Application (2018-2029)
5.2.1 Global Metabotropic Glutamate Antagonists Revenue by Application (2018-2023)
5.2.2 Global Metabotropic Glutamate Antagonists Revenue by Application (2024-2029)
5.2.3 Global Metabotropic Glutamate Antagonists Revenue Market Share by Application (2018-2029)
5.3 Global Metabotropic Glutamate Antagonists Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Artemis Neuroscience
6.1.1 Artemis Neuroscience Corporation Information
6.1.2 Artemis Neuroscience Description and Business Overview
6.1.3 Artemis Neuroscience Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Artemis Neuroscience Metabotropic Glutamate Antagonists Product Portfolio
6.1.5 Artemis Neuroscience Recent Developments/Updates
6.2 VistaGen Therapeutics
6.2.1 VistaGen Therapeutics Corporation Information
6.2.2 VistaGen Therapeutics Description and Business Overview
6.2.3 VistaGen Therapeutics Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.2.4 VistaGen Therapeutics Metabotropic Glutamate Antagonists Product Portfolio
6.2.5 VistaGen Therapeutics Recent Developments/Updates
6.3 Rottapharm Madaus
6.3.1 Rottapharm Madaus Corporation Information
6.3.2 Rottapharm Madaus Description and Business Overview
6.3.3 Rottapharm Madaus Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Rottapharm Madaus Metabotropic Glutamate Antagonists Product Portfolio
6.3.5 Rottapharm Madaus Recent Developments/Updates
6.4 Amorsa Therapeutics
6.4.1 Amorsa Therapeutics Corporation Information
6.4.2 Amorsa Therapeutics Description and Business Overview
6.4.3 Amorsa Therapeutics Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Amorsa Therapeutics Metabotropic Glutamate Antagonists Product Portfolio
6.4.5 Amorsa Therapeutics Recent Developments/Updates
6.5 Newron Pharmaceuticals
6.5.1 Newron Pharmaceuticals Corporation Information
6.5.2 Newron Pharmaceuticals Description and Business Overview
6.5.3 Newron Pharmaceuticals Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Newron Pharmaceuticals Metabotropic Glutamate Antagonists Product Portfolio
6.5.5 Newron Pharmaceuticals Recent Developments/Updates
6.6 Purdue Biopharma
6.6.1 Purdue Biopharma Corporation Information
6.6.2 Purdue Biopharma Description and Business Overview
6.6.3 Purdue Biopharma Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Purdue Biopharma Metabotropic Glutamate Antagonists Product Portfolio
6.6.5 Purdue Biopharma Recent Developments/Updates
6.7 Relmada Therapeutics
6.6.1 Relmada Therapeutics Corporation Information
6.6.2 Relmada Therapeutics Description and Business Overview
6.6.3 Relmada Therapeutics Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Relmada Therapeutics Metabotropic Glutamate Antagonists Product Portfolio
6.7.5 Relmada Therapeutics Recent Developments/Updates
6.8 BioCrea GmbH
6.8.1 BioCrea GmbH Corporation Information
6.8.2 BioCrea GmbH Description and Business Overview
6.8.3 BioCrea GmbH Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.8.4 BioCrea GmbH Metabotropic Glutamate Antagonists Product Portfolio
6.8.5 BioCrea GmbH Recent Developments/Updates
6.9 Cerecor Inc.
6.9.1 Cerecor Inc. Corporation Information
6.9.2 Cerecor Inc. Description and Business Overview
6.9.3 Cerecor Inc. Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Cerecor Inc. Metabotropic Glutamate Antagonists Product Portfolio
6.9.5 Cerecor Inc. Recent Developments/Updates
6.10 NeurOp Inc.
6.10.1 NeurOp Inc. Corporation Information
6.10.2 NeurOp Inc. Description and Business Overview
6.10.3 NeurOp Inc. Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.10.4 NeurOp Inc. Metabotropic Glutamate Antagonists Product Portfolio
6.10.5 NeurOp Inc. Recent Developments/Updates
6.11 UCB SA
6.11.1 UCB SA Corporation Information
6.11.2 UCB SA Metabotropic Glutamate Antagonists Description and Business Overview
6.11.3 UCB SA Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.11.4 UCB SA Metabotropic Glutamate Antagonists Product Portfolio
6.11.5 UCB SA Recent Developments/Updates
6.12 Novartis AG
6.12.1 Novartis AG Corporation Information
6.12.2 Novartis AG Metabotropic Glutamate Antagonists Description and Business Overview
6.12.3 Novartis AG Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Novartis AG Metabotropic Glutamate Antagonists Product Portfolio
6.12.5 Novartis AG Recent Developments/Updates
6.13 Luc Therapeutics Inc.
6.13.1 Luc Therapeutics Inc. Corporation Information
6.13.2 Luc Therapeutics Inc. Metabotropic Glutamate Antagonists Description and Business Overview
6.13.3 Luc Therapeutics Inc. Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Luc Therapeutics Inc. Metabotropic Glutamate Antagonists Product Portfolio
6.13.5 Luc Therapeutics Inc. Recent Developments/Updates
6.14 Evotec AG
6.14.1 Evotec AG Corporation Information
6.14.2 Evotec AG Metabotropic Glutamate Antagonists Description and Business Overview
6.14.3 Evotec AG Metabotropic Glutamate Antagonists Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Evotec AG Metabotropic Glutamate Antagonists Product Portfolio
6.14.5 Evotec AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Metabotropic Glutamate Antagonists Industry Chain Analysis
7.2 Metabotropic Glutamate Antagonists Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Metabotropic Glutamate Antagonists Production Mode & Process
7.4 Metabotropic Glutamate Antagonists Sales and Marketing
7.4.1 Metabotropic Glutamate Antagonists Sales Channels
7.4.2 Metabotropic Glutamate Antagonists Distributors
7.5 Metabotropic Glutamate Antagonists Customers
8 Metabotropic Glutamate Antagonists Market Dynamics
8.1 Metabotropic Glutamate Antagonists Industry Trends
8.2 Metabotropic Glutamate Antagonists Market Drivers
8.3 Metabotropic Glutamate Antagonists Market Challenges
8.4 Metabotropic Glutamate Antagonists Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
